Business Model Breakdown
How ACADIA Pharmaceuticals Inc Makes Money
ACAD
Market Cap
$3.8B
Annual Revenue
$1.0B
Profit Margin
45.0%
The Short Version
ACADIA Pharmaceuticals is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for central nervous system (CNS) disorders and rare diseases. The company generates its revenue primarily from the sales of two FDA-approved drugs: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis, and DAYBUE (trofinetide) for Rett Syndrome. Their business model involves extensive research and development to identify and advance promising drug candidates through clinical trials, obtain regulatory approvals, and then commercialize these medicines through a dedicated sales and marketing infrastructure aimed at healthcare providers and patients.
Where the Revenue Comes From
NUPLAZID sales (Primary revenue stream)
DAYBUE (trofinetide) sales (Significant and growing revenue stream)
Who buys: Patients suffering from CNS disorders and rare diseases, primarily reached through prescriptions from neurologists, psychiatrists, and other specialist physicians.
Why It Works (Competitive Advantages)
- ✔Proprietary drugs with regulatory exclusivity (DAYBUE orphan drug status).
- ✔Established commercial infrastructure and expertise in CNS disorders.
- ✔Pipeline focused on areas of high unmet medical need (e.g., Alzheimer's Disease Psychosis).
Economic Moat: Narrow (Intangible Assets (IP and regulatory exclusivity for approved drugs, especially DAYBUE), Switching Costs (for patients established on NUPLAZID))
What Our Analysis Says
DVR Score as of April 30, 2026
ACADIA Pharmaceuticals presents a high-risk, high-reward opportunity, but recent developments have slightly tempered its 10x growth potential. The Q4 2025 earnings beat and strong profitability metrics (36.49% net margin, 12.49% ROE) demonstrate a solid financial base from existing products like DAYBUE, further boosted by the US launch of DAYBUE STIX. The substantial 10x potential remains tied to the success of NUPLAZID in Alzheimer's Disease Psychosis, which represents a massive unmet market but carries high clinical development risk. However, the European Medicines Agency's negative opinion on trofinetide for Rett Syndrome significantly impacts DAYBUE's international expansion, limiting a key growth vector. While management has a proven track record, the R&D head's upcoming retirement and mixed analyst sentiment (BofA's lowered PT despite an upgrade) add elements of caution. The company's future hinges on its pipeline, particularly NUPLAZID for ADP, making it a binary bet with reduced geographic diversification for its current growth driver.